Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16887859 | 0.80 | ALDH1A1 (0.36) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL28033967 | 0.72 | ALDH1A1 (0.34) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL16887861 | 0.72 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL15630516 | 0.71 | ALDH1A1 (0.36) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL28647073 | 0.69 | TDP1 (0.48) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL10796673 | 0.69 | ALDH1A1 (0.41) | MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL10806369 | 0.68 | MAPT (0.42) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL7606757 | 0.67 | ERBB2 (0.41) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL9134809 | 0.67 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTHPGDALOX12 | |
| SCHEMBL27594442 | 0.67 | TDP1 (0.40) | MEN1ALDH1A1MAPTHPGDALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311895-B1 | BIOMATERIALS FORMED BY NUCLEOPHILIC ADDITION REACTION TO CONJUGATED UNSATURATED GROUPS | Eidgenössische Technische Hochschule Zürich (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-9180222-B2 | Polymeric tissue sealant | KUROS BIOSURGERY AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150133579-A1 | Polymeric Tissue Sealant | KUROS BIOSURGERY AG (CH) | 2015-05-14 | — | — | US | disclosed |
| US-8961947-B2 | Polymeric tissue sealant | KUROS BIOSURGERY AG (CH) | 2015-02-24 | — | — | US | disclosed |
| US-20140343324-A1 | SYNTHETIC MATRIX FOR CONTROLLED CELL INGROWTH AND TISSUE REGENERATION | Eidgenossische Technische Hochschule Zürich (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20130243878-A1 | BIOMATERIALS FOR DELIVERY OF BLOOD EXTRACTS AND METHODS OF USING SAME | MOSAIC BIOSCIENCES, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2537539-A1 | Polymeric Tissue Sealant | Kuros Biosurgery AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8282912-B2 | Compositions for tissue augmentation | Kuros Biosurgery, AG (CH) | 2012-10-09 | — | — | US | disclosed |
| EP-2136850-B1 | POLYMERIC TISSUE SEALANT | KUROS BIOSURGERY AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| EP-1292709-B1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EIDGENOESS TECH HOCHSCHULE (CH) | 2012-01-18 | — | — | EP | disclosed |
| US-7744912-B1 | Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2010-06-29 | — | — | US | disclosed |
| US-7670605-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2010-03-02 | — | — | US | disclosed |
| US-20100034769-A1 | COMPOSITIONS FOR TISSUE AUGMENTATION | Kuros Biosurgery, AG | 2010-02-11 | — | — | US | disclosed |
| US-7575740-B2 | Compositions for tissue augmentation | KUROS BIOSURGERY AG (CH) | 2009-08-18 | — | — | US | disclosed |
| US-20090098083-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | UNIVERSITAT ZURICH (CH) | 2009-04-16 | — | — | US | disclosed |
| WO-2008125655-A1 | POLYMERIC TISSUE SEALANT | KUROS BIOSURGERY AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-20080253987-A1 | Biomaterial from precursors pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl and an ethylene oxide-propylene oxide star polymer having ethylene diamine as the nucleus and acrylate end groups; containing biological fluids or gases; nonswelling, high mechanical strength, biocompatability | KUROS BIOSURGERY AG | 2008-10-16 | — | — | US | disclosed |
| US-7413739-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20070264227-A1 | Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH | 2007-11-15 | — | — | US | disclosed |
| US-7291673-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343324-A1 | SYNTHETIC MATRIX FOR CONTROLLED CELL INGROWTH AND TISSUE REGENERATION | FGF2, EPCAM, FGF1 | MEN1 2551/4885ALDH1A1 1296/4885MAPT 4268/4885 |
| US-20130243878-A1 | BIOMATERIALS FOR DELIVERY OF BLOOD EXTRACTS AND METHODS OF USING SAME | PDGFA, PGF, MATR3 | MEN1 2384/4885ALDH1A1 3646/4885MAPT 1777/4885 |
| US-20070264227-A1 | Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration | FGF2, EPCAM, FGF1 | MEN1 2551/4885ALDH1A1 1296/4885MAPT 4268/4885 |
| US-20080253987-A1 | Biomaterial from precursors pentaerythritol poly(ethylene glycol)ether tetra-sulfhydryl and an ethylene oxide-propylene oxide star polymer having ethylene diamine as the nucleus and acrylate end groups; containing biological fluids or gases; nonswelling, high mechanical strength, biocompatability | PAM, BMP6, PTGER1 | MEN1 2311/4885ALDH1A1 3596/4885MAPT 4335/4885 |
| US-20100034769-A1 | COMPOSITIONS FOR TISSUE AUGMENTATION | BMP2, BMX, PTMS | MEN1 1926/4885ALDH1A1 424/4885MAPT 4051/4885 |
| US-20090098083-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | PAICS, COASY, LIPA | MEN1 2621/4885ALDH1A1 409/4885MAPT 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.